Open AccessPre‐ and Postexposure Use of Human Monoclonal Antibody against H5N1 and H1N1 Influenza Virus in Mice: Viable Alternative to Oseltamivir
Author(s) -
Wouter Koudstaal,
Martin H. Koldijk,
Just P. J. Brakenhoff,
Lisette A. H. M. Cornelissen,
Gerrit Jan Weverling,
Robert H. Friesen,
Jaap Goudsmit
Publication year - 2009
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/648378
Subject(s) - oseltamivir , virology , monoclonal antibody , influenza a virus subtype h5n1 , virus , influenza a virus , medicine , antibody , orthomyxoviridae , neutralizing antibody , immunology , biology , covid-19 , infectious disease (medical specialty) , disease
New strategies to prevent and treat influenza virus infections are urgently needed. A recently discovered class of monoclonal antibodies (mAbs) neutralizing an unprecedented spectrum of influenza virus subtypes may have the potential for future use in humans. Here, we assess the efficacies of CR6261, which is representative of this novel class of mAbs, and oseltamivir in mice. We show that a single injection with 15 mg/kg CR6261 outperforms a 5-day course of treatment with oseltamivir (10 mg/kg/day) with respect to both prophylaxis and treatment of lethal H5N1 and H1N1 infections. These results justify further preclinical evaluation of broadly neutralizing mAbs against influenza virus for the prevention and treatment of influenza virus infections.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom